Haemophilia therapy from largest multi-year donation now available to patients in developing world

World Federation of Hemophilia announces expansion of humanitarian aid programme. Biogen, Sobi and the World Federation of Hemophilia collaboration to enable a sustained humanitarian supply of haemophilia treatment with the potential to change treatment paradigm in developing countries.

The first shipments of much-needed haemophilia therapy have started to arrive at treatment centers across the developing world Biogen (NASDAQ: BIIB), Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) and the World Federation of Hemophilia (WFH) announced today. These shipments are part of the largest humanitarian aid pledge of its kind to help people with haemophilia in developing countries.

The donation will provide up to 500 million units of haemophilia therapy over five years to the WFH and represents a significant contribution to the expansion of their Humanitarian Aid Program, a 20-year old initiative dedicated to providing treatment and care for people with haemophilia in the developing world. This initiative is the first phase of Biogen and Sobi’s ten-year commitment to produce 1 billion International Units (IUs) of haemophilia therapy for humanitarian use.

Haemophilia is a rare, chronic, inherited disorder in which the ability of a person’s blood to clot is impaired. The WFH donation program is designed to create a sustainable model for humanitarian aid that has the potential to improve haemophilia care in regions of the world where, due to limited access to diagnosis and treatment, people with severe haemophilia often do not survive to adulthood. This donation is intended to help enable a predictable and sustainable supply of therapy to countries in need, and is the first time treatment clinics will receive product manufactured specifically for humanitarian use. The first recipient countries of the donation include Senegal, Kenya, Philippines, Dominican Republic, Uzbekistan, Jordan, Egypt, Morocco, Pakistan, El Salvador, Indonesia, Ghana, Myanmar, India, Sri Lanka and Nigeria.

“The majority of people with haemophilia in developing countries do not live past adulthood and if they do, they face a life of severe disability and chronic pain,” said Assad E. Haffar, M.D., WFH Humanitarian Aid Program Director. “The lack of access to clotting factor concentrates in these countries presents an urgent and important public health challenge.”

“By expanding the WFH Humanitarian Aid Program through larger and more predictable donations, we may now be in a position to create a foundation for more sustainable and improved care in parts of the world where there is an urgent need,” said WFH President Alain Weill.

According to the WFH, an estimated 400,000 people worldwide have haemophilia and of these, more than 300,000 individuals live in areas where there is limited access to diagnosis and treatment. This commitment from Biogen and Sobi and the steady flow of medicine to WFH may help enable access to treatment for emergency situations, acute bleeds, elective surgeries and also prophylaxis for children.

“The WFH has made great strides in advancing the care for people with haemophilia in developing countries over the last two decades, and we are proud to help them accelerate their efforts,” remarked John Cox, executive vice president, Pharmaceutical Operations and Technology at Biogen. “This is a significant milestone in our joint effort with the WFH and our hope is that others will join us to help create a sustainable model for humanitarian support.”

“We regard healthcare innovation as a global commitment. By helping to address the global treatment gap and supporting the WFH’s mission of treatment for all, we hope to enable meaningful change for people with haemophilia across the world,” said Geoffrey McDonough, president and chief executive officer of Sobi.

- - -

About the World Federation of Hemophilia

For over 50 years, the World Federation of Hemophilia (WFH), an international not-for-profit organisation, has worked to improve the lives of people with haemophilia and other inherited bleeding disorders. Established in 1963, it is a global network of patient organisations in 127 countries and has official recognition from the World Health Organization. Visit WFH online at www.wfh.org

About Biogen

Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative haemophilia therapies. For product labelling, press releases and additional information about the company, please visit www.biogen.com.

About Sobi

Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.

For more information please contact